Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
octadecyltrimethylammonium bromide is a synthetic quaternary ammonium surfactant consisting of a long C18 alkyl chain attached to a trimethylammonium head group with bromide as the counter‑ion. It is widely used as a cationic surfactant, emulsifier, phase‑transfer catalyst, disinfectant, and bactericide in chemical and materials applications, and in research it is employed as a small‑molecule inhibitor of the GTPase dynamin I with micromolar potency.[2][7][10][12][13][14] Its amphiphilic structure enables micelle formation and strong interactions with biological membranes, which underlie both its surfactant properties and its ability to interfere with endocytosis pathways via dynamin inhibition.[2][4][13][14]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on octadecyltrimethylammonium bromide.